MajorAntianginal – late sodium current inhibitor×HMG-CoA reductase inhibitors (statins)
Updated · Methodology
Mechanism
The metabolism and clearance of simvastatin depend heavily on CYP3A4 (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). Ranolazine is a weak CYP3A4 inhibitor and also inhibits the transporter P-glycoprotein (P-gp), so it may raise levels of drugs metabolised by CYP3A4 (EMA). Ranolazine 1000 mg twice daily doubled the levels of simvastatin and of its active form, simvastatin acid (EMA). According to the US simvastatin label, the area under the concentration-time curve (AUC) of simvastatin acid rose 2.26-fold and that of simvastatin 1.86-fold (simvastatin label, US Food and Drug Administration, FDA). The higher the blood levels of simvastatin and simvastatin acid, the higher the risk of muscle damage (simvastatin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Symptoms
Simvastatin myopathy presents as muscle pain, tenderness or weakness with creatine kinase (CK) above ten times the upper limit of normal. It sometimes progresses to rhabdomyolysis, with or without acute kidney failure due to myoglobinuria, and deaths have occurred very rarely (simvastatin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Post-marketing reports describe rhabdomyolysis in patients taking ranolazine and simvastatin (ranolazine SmPC, European Medicines Agency, EMA). The risk of myopathy is higher at age 65 or older, with renal impairment, with uncontrolled hypothyroidism and with higher simvastatin doses (simvastatin label, US Food and Drug Administration, FDA).
Management
Limit the simvastatin dose. With any dose of ranolazine, give no more than 20 mg of simvastatin once daily (ranolazine summary of product characteristics, SmPC, European Medicines Agency, EMA). The US ranolazine and simvastatin labels have the same rule (ranolazine and simvastatin labels, US Food and Drug Administration, FDA). The Spanish simvastatin SmPC does not name ranolazine. It says to switch to a lower simvastatin dose or to another statin with fewer interactions if an interacting drug has to be added to simvastatin 80 mg (simvastatin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Warn the patient about the risk of muscle damage. If muscle pain, weakness or cramps occur, measure creatine kinase (CK), and stop simvastatin if CK is more than five times the upper limit of normal without strenuous exercise (AEMPS). With severe muscle symptoms, consider stopping simvastatin even at lower CK, and stop it if myopathy is suspected for any other reason (AEMPS). Measure CK before starting simvastatin if there are risk factors for rhabdomyolysis: age 65 or older, female sex, renal impairment, uncontrolled hypothyroidism, a personal or family history of hereditary muscle disorders, previous muscle toxicity with a statin or a fibrate, or alcohol abuse (AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Ranolazine extended-release tablets (Zydus Lifesciences) – prescribing information (2026)– FDA label, Zydus Lifesciences, DailyMed setid d74f3dea-7357-4e9a-be9a-2f498a44108a, version 5, 09/2026, sections 2.2, 4, 5.1, 7.1 and 7.2
- FDA: Zocor (simvastatin) tablets – Prescribing Information (2025)– FDA, DailyMed SPL, Organon, sections 2.5, 4, 5.1 and 7.1
- AEMPS: Ficha técnica: Simvastatina, Zocor 10 mg (nº registro 58845), sección 4.4 (2026)– AEMPS, CIMA, nº registro 58845 (Zocor 10 mg comprimidos recubiertos con película, Organon Salud), revisión 06/2026, secciones 4.2, 4.4, 4.5 y 5.2
- EMA: Ficha técnica: Ranolazina, Ranexa (EU/1/08/462), sección 4.5 (2026)– EMA, Ranexa 375 mg comprimidos de liberación prolongada (Menarini International Operations Luxembourg, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 08462001, consultada 24.10.2026, sin fecha de revisión en CIMA, secciones 4.2, 4.4, 4.5, 4.8, 4.9 y 5.2